External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes
Semaglutide treatment was linked to a significantly lower risk of clinically relevant renal outcomes. Our findings provide robust real-world evidence that supports the FLOW trial results regarding the renoprotective effects of semaglutide, highlighting its promise as an effective therapeutic option for managing renal complications.
Authors
- Onur Başer (ORCID: https://orcid.org/0000-0001-7447-5672)
- Yuanqing Lu (ORCID: https://orcid.org/0000-0001-8196-8918)
Institutions
- City University of New York (US)
- Boğaziçi University (TR)
Publication Details
- Journal
- Expert Opinion on Pharmacotherapy
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1080/14656566.2025.2518329
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00